Incretin Atlas › Trials › ZUPREME-1
ZUPREME-1
Petrelintide · obesity
Design
- Molecule(s)
- Petrelintide
- Population
- obesity
- Phase
- 2
- Duration
- 28 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| petrelintide 1.0 mg | obesity | 28 | — | −7.9 % vs −1.7 % Δ −6.2 pp | — | — | 5.0 vs 5.0 | 16.5 vs 24.7 | 19.0 vs 6.0 | 4.0 vs 6.0 | 3.0 vs 4.0 | — | verified |
| petrelintide 2.5 mg | obesity | 28 | — | −7.9 % vs −1.7 % Δ −6.2 pp | — | — | 1.0 vs 5.0 | 11.1 vs 24.7 | 12.0 vs 6.0 | 0.0 vs 6.0 | 1.0 vs 4.0 | — | verified |
| petrelintide 5.0 mg | obesity | 28 | — | −9.8 % vs −1.7 % Δ −8.1 pp | — | — | 5.0 vs 5.0 | 9.6 vs 24.7 | 23.0 vs 6.0 | 0.0 vs 6.0 | 6.0 vs 4.0 | — | verified |
| petrelintide 7.0 mg | obesity | 28 | — | −9.3 % vs −1.7 % Δ −7.6 pp | — | — | 1.0 vs 5.0 | 12.7 vs 24.7 | 15.0 vs 6.0 | 3.0 vs 6.0 | 4.0 vs 4.0 | — | verified |
| petrelintide 9.0 mg | obesity | 28 | — | −9.4 % vs −1.7 % Δ −7.7 pp | — | — | 10.0 vs 5.0 | 18.3 vs 24.7 | 28.0 vs 6.0 | 9.0 vs 6.0 | 4.0 vs 4.0 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- petrelintide 1.0 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide 2.5 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide 5.0 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide 7.0 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide 9.0 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
Verbatim quotes from the source (30)
- petrelintide 1.0 mg · weight_eff · Abstract; Table 2
−7·9% (95% CI −9·0 to −6·7) with petrelintide 1·0 mg
- petrelintide 1.0 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 1.0 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 1.0 mg · vomiting · Table 3
Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
- petrelintide 1.0 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 1.0 mg · disc_any · Figure 1 (trial profile)
13 discontinued treatment 4 adverse events
- petrelintide 2.5 mg · weight_eff · Abstract; Table 2
−7·9% (−9·0 to −6·7) with petrelintide 2·5 mg
- petrelintide 2.5 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 2.5 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 2.5 mg · vomiting · Table 3
Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
- petrelintide 2.5 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 2.5 mg · disc_any · Figure 1 (trial profile)
9 discontinued treatment 4 lack of efficacy 4 other 1 adverse event
- petrelintide 5.0 mg · weight_eff · Abstract; Table 2
−9·8% (−10·9 to −8·6) with petrelintide 5·0 mg
- petrelintide 5.0 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 5.0 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 5.0 mg · vomiting · Table 3
Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
- petrelintide 5.0 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 5.0 mg · disc_any · Figure 1 (trial profile)
8 discontinued treatment 4 adverse events
- petrelintide 7.0 mg · weight_eff · Abstract; Table 2
−9·3% (−10·5 to −8·2) with petrelintide 7·0 mg
- petrelintide 7.0 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 7.0 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 7.0 mg · vomiting · Table 3
Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
- petrelintide 7.0 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 7.0 mg · disc_any · Figure 1 (trial profile)
10 discontinued treatment 7 other 1 adverse event
- petrelintide 9.0 mg · weight_eff · Abstract; Table 2
−9·4% (−10·5 to −8·3) with petrelintide 9·0 mg
- petrelintide 9.0 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 9.0 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 9.0 mg · vomiting · Results, paragraph 10; Table 3
The petrelintide 9·0 mg group was the only group in which the incidence of vomiting (seven [9%] of 82) exceeded that observed with placebo
- petrelintide 9.0 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 9.0 mg · disc_any · Figure 1 (trial profile)
15 discontinued treatment 8 adverse events
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: ZUPREME-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/zupreme-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.